Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.

Journal of translational medicine - 3 Sept 2015

Normanno Nicola, Pinto Carmine, Castiglione Francesca, Fenizia Francesca, Barberis Massimo, Marchetti Antonio, Fontanini Gabriella, De Rosa Gaetano, Taddei Gian Luigi

Abstract excerpt

BACKGROUND: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for the selection of metastatic colorectal cancer (mCRC) patients eligible for the therapy with anti-EGFR monoclonal antibodies. The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytology (SIAPEC) organized an external quality assessment (EQA) scheme for CRC to evaluate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Europe
Share to False Positive Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Formaldehyde

Share to Genes, ras

Share to Models, Statistical

Share to Neoplasm Metastasis

Share to Quality Control

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26335936
DOI: 10.1186/s12967-015-0655-1
PMCID: PMC4557483

Genes

KRAS
NRAS
BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.PMID 26335936Read ↗

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.Semantic proximity Read ↗

Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.Semantic proximity Read ↗

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.Semantic proximity Read ↗

The RAS testing in real world management of metastatic colorectal cancer: The results of Italian Laboratories Survey.Semantic proximity Read ↗

External quality assessment for EGFR mutations in Italy: improvements in performances over the timeSemantic proximity Read ↗

Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer.Semantic proximity Read ↗

RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.Semantic proximity Read ↗

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.Semantic proximity Read ↗

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.Semantic proximity Read ↗

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.Semantic proximity Read ↗

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.